Former President and CEO · REGENXBIO Inc. (RGNX)

Kenneth Mills

A named executive officer of REGENXBIO in every fiscal year CompBrief holds from FY2016 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$5,507,038

Salary $340,998Stock awards $1,175,649

FY2023: $5,916,713

1st of 7 named executive officers at Regenxbio by FY2024 total.

7 named officers on file for REGENXBIO, FY2024

Kenneth Mills’s pay file — $29

  • 9 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • RGNX’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how REGENXBIO’s whole pay program stands against its peers

  • REGENXBIO’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RGNX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Kenneth Mills’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kenneth Mills compensation by year

REGENXBIO Summary Compensation Table · all 9 fiscal years held
In US dollars, as REGENXBIO reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Salary$514,890$530,450$546,364$595,537$613,403$631,805$650,759$676,790$340,998
Bonus$0$0$0$0$0$600,000$0$0$0
Stock awards$0$0$0$0$0$1,843,050$1,228,161$1,218,254$1,175,649
Option awards$1,979,413$1,734,200$3,895,222$5,160,444$6,646,254$5,057,556$3,505,846$3,698,138$3,489,594
Non-equity incentive$206,000$278,486$480,800$375,188$368,042$473,854$351,410$304,555$406,074
Pension and deferred compensation$0$0$0$0$0$0$0$0$0
All other$17,706$15,525$15,813$16,100$16,388$16,675$17,538$18,975$94,723
Total$2,718,009$2,558,661$4,938,199$6,147,269$7,644,087$8,622,941$5,753,713$5,916,713$5,507,038

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENXBIO Inc. DEF 14A filed April 8, 2025, accession 0000950170-25-052069, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENXBIO Inc. filed document, accession 0000950170-25-052069. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2025.

$2.7M
$2.6M
$4.9M
$6.1M
$7.6M
$8.6M
$5.8M
$5.9M
$5.5M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU64,103$495,516—
RSU41,065$317,432—
RSU17,898$138,352—
RSU10,246$79,202—
Option3,858—$44.97
Option305,250—$18.34
Option46,093—$34.31
Option137,985—$22.25

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENXBIO Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

10 Form 4 lines since the FY2024 proxy (filed April 8, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-29Grant or award—9,807$0.00495,925
2026-05-29Grant or award derivative—46,600$0.0046,600
2026-01-27Exercise or conversion derivative—225,000$0.00225,000
2026-01-27Tax withholding—221,753$13.41486,118
2026-01-27Exercise or conversion—225,000$13.09707,871
2025-05-30Grant or award—7,768$0.00482,871
2025-05-30Grant or award derivative—39,815$0.0039,815
2025-05-12Exercise or conversion10b5-120,602$3.76495,705

The 8 most recent of 10 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

REGENXBIO’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kenneth Mills · this pageFormer President and CEO$5,507,038
Curran SimpsonPresident and Chief Executive Officer$4,784,543
Mitchell ChanEVP, Chief Financial Officer$3,205,294
Olivier DanosEVP, Chief Scientific Officer$2,956,949
Patrick ChristmasEVP, Chief Strategy and Legal Officer$2,737,813
Stephen PakolaEVP, Chief Medical Officer$2,696,858
Vit VasistaFormer EVP, Chief Financial Officer$2,226,951

Board service

REGENXBIO board · FY2021–FY2025
Director compensation in US dollars, as REGENXBIO reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$80,000$68,747$206,247$0$354,994
FY2024$40,000$0$0—$40,000
FY2023—————
FY2022—————
FY2021—————

Each year as the company reported it in REGENXBIO's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: REGENXBIO pays directors a $45,000 cash retainer and $275,000 in Options and RSUs. As stated in REGENXBIO's FY2025 proxy.

The full REGENXBIO compensation record

free company brief

This page is one person within REGENXBIO's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENXBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kenneth Mills's compensation dossier · One-time report. No refunds.